View Financial HealthAdia Nutrition 배당 및 자사주 매입배당 기준 점검 0/6Adia Nutrition 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.4%자사주 매입 수익률총 주주 수익률-0.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 08Adia Nutrition, Inc. Appoints Dawn Bell as Chief Revenue OfficerAdia Nutrition, Inc. announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships. While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties. This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts.공시 • Oct 22Adia Nutrition, Inc. Appoints Evan Thomas as Independent Medical Director for Its Medical Division, Adia MedAdia Nutrition, Inc. announced the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers. Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology &Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care.공시 • Sep 11Adia Nutrition, Inc. Appoints Richard Edwards as Its Second Medical DirectorAdia Nutrition, Inc. announced the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards joins Dr. Monica Sher, MD, to form a diverse and highly experienced board of medical directors. This strategic expansion underscores Adia Nutritions commitment to providing exceptional care and advancing innovative treatments in the field of autologous Hematopoietic Stem Cell Transplantation (aHSCT). Dr. Edwards, a distinguished osteopathic physician, complements Dr. Shers medical expertise with his unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align seamlessly with Adia Nutritions mission to deliver comprehensive and individualized treatment plans. Adia Nutrition is set to move forward with its next crucial step: recruiting oncologists to administer aHSCT treatments. The board and the oncologists will collaborate to review and select the safest and most effective aHSCT protocols from around the world (over 10,000 patients treated by aHSCT worldwide). They will be responsible for crafting detailed protocols and procedures tailored specifically for Adia Nutritions clinics. This process will include determining whether treatments will be administered in a hospital setting or an outpatient clinic, ensuring that all options provide the highest standards of care. In addition to protocol development, the board of medical directors will also be actively involved in evaluating potential patients. Through a thorough assessment process, they will determine which individuals are suitable candidates for aHSCT treatments, based on their medical history and treatment needs.공시 • Aug 23Adia Nutrition, Inc. Announces Appointment of Dr. Monica Sher as One of the Directors of Its Medical DivisionAdia Nutrition, Inc. announced appointment of Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients. Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.공시 • Apr 20Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 75,000,000 Price\Range: $0.005 to $0.02 Discount Per Security: $0지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ADIA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ADIA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Adia Nutrition 배당 수익률 vs 시장ADIA의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ADIA)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Personal Products)3.4%분석가 예측 (ADIA) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ADIA 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ADIA 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ADIA 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ADIA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 21:44종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Adia Nutrition, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 08Adia Nutrition, Inc. Appoints Dawn Bell as Chief Revenue OfficerAdia Nutrition, Inc. announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships. While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties. This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts.
공시 • Oct 22Adia Nutrition, Inc. Appoints Evan Thomas as Independent Medical Director for Its Medical Division, Adia MedAdia Nutrition, Inc. announced the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers. Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology &Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care.
공시 • Sep 11Adia Nutrition, Inc. Appoints Richard Edwards as Its Second Medical DirectorAdia Nutrition, Inc. announced the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards joins Dr. Monica Sher, MD, to form a diverse and highly experienced board of medical directors. This strategic expansion underscores Adia Nutritions commitment to providing exceptional care and advancing innovative treatments in the field of autologous Hematopoietic Stem Cell Transplantation (aHSCT). Dr. Edwards, a distinguished osteopathic physician, complements Dr. Shers medical expertise with his unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align seamlessly with Adia Nutritions mission to deliver comprehensive and individualized treatment plans. Adia Nutrition is set to move forward with its next crucial step: recruiting oncologists to administer aHSCT treatments. The board and the oncologists will collaborate to review and select the safest and most effective aHSCT protocols from around the world (over 10,000 patients treated by aHSCT worldwide). They will be responsible for crafting detailed protocols and procedures tailored specifically for Adia Nutritions clinics. This process will include determining whether treatments will be administered in a hospital setting or an outpatient clinic, ensuring that all options provide the highest standards of care. In addition to protocol development, the board of medical directors will also be actively involved in evaluating potential patients. Through a thorough assessment process, they will determine which individuals are suitable candidates for aHSCT treatments, based on their medical history and treatment needs.
공시 • Aug 23Adia Nutrition, Inc. Announces Appointment of Dr. Monica Sher as One of the Directors of Its Medical DivisionAdia Nutrition, Inc. announced appointment of Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients. Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.
공시 • Apr 20Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 75,000,000 Price\Range: $0.005 to $0.02 Discount Per Security: $0